SCHEMBL459532

SCHEMBL459532

[CH2]C(=O)c1ccc(OCC(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.61
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
FFAR1 O14842 1/20 0.55
PTPN7 P35236 2/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
PTPN12 Q05209 1/20 0.53
TSHR P16473 1/20 0.50
NR4A1 P22736 1/20 0.50
APEX1 P27695 1/20 0.50
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP19A1 P11511 1/20 0.48
ESR1 P03372 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL339492 0.85 ALOX15 (0.81) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL1532777 0.84 PARP10 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL29051537 0.83 ALOX15 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL16035699 0.83 ALOX15 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL5827387 0.83 ALOX15 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL341847 0.83 ALOX15 (0.65) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL5321036 0.81 ALOX15 (0.57) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL459533 0.80 L3MBTL1 (0.66) ALOX15ALDH1A1SMN1; SMN2FFAR1MAPT
SCHEMBL1965751 0.80 ALOX15 (0.61) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7
SCHEMBL7832502 0.79 ALOX15 (0.55) ALOX15ALDH1A1SMN1; SMN2FFAR1PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9182385-B2 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2015-11-10 US claimed
US-8778620-B2 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2014-07-15 US claimed
US-20130130279-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2013-05-23 US claimed
US-20120309029-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2012-12-06 US claimed
US-8227202-B2 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2012-07-24 US claimed
EP-2304436-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT Nodality, Inc. (US) 2011-04-06 EP claimed
EP-2179037-A2 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT Nodality, Inc. (US) 2010-04-28 EP claimed
WO-2010006291-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT NODALITY, INC. (US) 2010-01-14 WO claimed
US-20100009364-A1 Methods for diagnosis, prognosis and methods of treatment NODALITY, INC. (US) 2010-01-14 US claimed
US-20090098594-A1 Methods for diagnosis prognosis and methods of treatment NODALITY, INC. (US) 2009-04-16 US claimed
WO-2009025847-A2 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2009-02-26 WO claimed
US-20170370933-A1 METHODS AND COMPOSITIONS FOR IMMUNOMODULATION NODALITY INC (US) 2017-12-28 US disclosed
US-20170370934-A1 METHODS AND COMPOSITIONS FOR IMMUNOMODULATION NODALITY INC (US) 2017-12-28 US disclosed
US-20170363633-A1 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY INC (US) 2017-12-21 US disclosed
US-20170350911-A1 HIGH THROUGHPUT FLOW CYTOMETRY SYSTEM AND METHOD NODALITY INC (US) 2017-12-07 US disclosed
WO-2009134944-A2 METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL NODALITY, INC. (US) 2009-11-05 WO disclosed
US-20090269773-A1 METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL NODALITY, INC. A DELAWARE CORPORATION 2009-10-29 US disclosed
US-20090269800-A1 DEVICE AND METHOD FOR PROCESSING CELL SAMPLES NODALITY, INC. 2009-10-29 US disclosed
US-20090098594-A1 Methods for diagnosis prognosis and methods of treatment NODALITY, INC. (US) 2009-04-16 US disclosed
WO-2009025847-A2 METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT NODALITY, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170370933-A1 METHODS AND COMPOSITIONS FOR IMMUNOMODULATION CD47, ICOS, CD74 ALOX15 685/4885ALDH1A1 1947/4885SMN1; SMN2 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.